In accordance with article 5 of the Spanish Law RDL1/2015, the information set out in the following sections is intended for healthcare professionals.

Access to this information and all use which may be made thereof or of these contents is exclusive responsibility of those who use them. Noventure will not be held liable for any illegal or improper use or for the manipulation of the contents and information included in these pages.

Magazine

Press Release: Noventure acquires Ulkox® and Oleoabrax®, two medical devices based on patented new wound-healing technology

•    Acquisition allows Noventure to maintain focus on medical devices and grow therapeutic areas in which it operates 
•    Medical devices contain Olea Europaea leaf extract, showing healing properties  for ulcers and skin wounds
•    Innovative products are CE marked and available for licensing worldwide

Barcelona, Spain, April 19, 2021 – Noventure, specialized in licensing innovative substance-based medical devices and specialist food supplements, today announces it has acquired the Ulkox® and Oleoabrax® products, based on an Olea Europaea leaf extract wound-healing technology. 

Read more
First launch of UTIPRO® PLUS AF in EUROPE

We are pleased to announce the launch of UTIPRO® PLUS AF in Portugal.
Portugal is the first European country in which UTIPRO® PLUS AF has been launched in its composition free from ingredients of animal origin. The product is distributed by Sangool, a Portuguese company specialized in the detailing and the distribution of high quality and innovative products, mainly addressed to women health and care.

Read more
Noventure is proud to announce the launch of XILAPLUS® in Estonia, Latvia and Lithuania by our partner company Miecys

Noventure is proud to announce the launch of XILAPLUS® in Estonia, Latvia and Lithuania by our partner company Miecys

XILAPLUS® is specifically formulated for the control and reduction of diarrheal events of various etiologies in adults, children, and infants.

Read more